Status:
UNKNOWN
VETC, Prognostic and Predictive Value in Renal Cell Carcinoma and Adrenal Carcinoma
Lead Sponsor:
Humanitas Clinical and Research Center
Conditions:
Renal Cell Carcinoma
Adrenal Carcinoma
Eligibility:
All Genders
Brief Summary
Metastasis is the main cause of death in cancer patients and often epithelial-to-mesenchymal transition (EMT) is advocated as the basic mechanism. Recently Fang and colleagues described an EMT-indepen...
Detailed Description
Background and introduction Metastasis is the main cause of death in cancer patients and often epithelial-to-mesenchymal transition (EMT) is advocated as the basic mechanism, although some limitation...
Eligibility Criteria
Inclusion
- Histological diagnosis of Renal Cell Carcinoma;
- Histological diagnosis of Carcinoma of the adrenal gland;
- Availability of histological material;
- For the evaluation of the prognostic role: no systemic treatment with TKI administered before surgery.
Exclusion
- Unavailable histological material;
- For RCC: histological diagnosis different from Clear Cell histotype.
Key Trial Info
Start Date :
January 2 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2021
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT04666220
Start Date
January 2 2021
End Date
May 1 2021
Last Update
February 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Humanitas Clinical and Research Hospital
Rozzano, MI, Italy, 20089